Anteris Technologies Global Corp AVR

$7.61 -0.16 (-2.06%)

Valuation

Market cap
757,249,000
Revenue TTM
$1,910,000
Net income TTM
$-94,140,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,928.80%
Debt to equity
0.00

Trading

Volume
1,170,600
Avg volume
801,608
Day's range
$7.52 – $7.86
Shares out
97,458,000
Stochastic %K
16%
Beta
1.80
Analysts
Strong Sell
Price target
$15.80

Price

Company profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissu...

Show more

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Industry
Medical Devices
Sector
Healthcare
Phone
61 7 3152 3200
Website
https://anteristech.com
Address
Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong, Australia

Latest news

Stocktwits

Orlandotrader Sep 23, 7:05 PM
$AVR So much for Buy and Hold. Glad I made some money. Will come back when we know what’s going on at the Company.
1 replies
Templar57 Sep 18, 7:58 AM
$AVR something to consider, the lack of published enrollment data for the Paradigm trial, may be on purpose. It’s common for competitive studies to not disclose site or enrollment information, because it alerts the competition to where the sites are located and who may be becoming a supporter. I believe the short interest, may get caught with their pants down.
1 replies
focafoca99 Sep 17, 9:21 PM
$AVR issued multiple equity incentive grants to executives, including stock options and performance RSUs.
1 replies
Orlandotrader Sep 17, 8:05 PM
$AVR Really would like some insight to Trial Enrollment. Volume stagnant and looking for some Direction and Guidance. I’ve heard from previous investors that companies like this don’t give any hints to Trial progress but it couldn’t hurt at this point or would it???? What’s happening at Anteris????
0 replies
Templar57 Sep 11, 3:57 AM
$AVR Medtronic CEO Geoff Martha discussed Anteris at the Wells Fargo conference and explicitly said that, to get into balloon-expandable TAVR, “we made the Anteris investment.”
0 replies
Templar57 Sep 8, 12:19 PM
$AVR Moen is exactly the kind of person I’d want sitting across the table from Medtronic, Abbott, Edwards—or Wall Street—if PARADIGM delivers. His contract is for 10 years and has a three year vesting, which is right in line with the values which could unlock with the Paradigm trial.
0 replies
focafoca99 Sep 8, 11:23 AM
$AVR named Brent Moen as its new CFO, effective Sep 11, with a $475K base salary and up to 50% bonus.
0 replies
Orlandotrader Aug 31, 7:21 PM
$AVR Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Cantor Global Healthcare Conference Wednesday, September 9, 2026 (US time) Format: Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings Time: 11:30AM (US EST) Wells Fargo Healthcare Conference Thursday, September 10, 2026 (US time) Format: Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings Time: 9:30AM (US EST)
0 replies